Sign in
Taking people in United StatesPhase 4

Testing pioglitazone or tirzepatide in normal-weight adults with type 2 diabetes

Tests two drugs in normal-weight adults with type 2 diabetes.

Key facts

Who runs it
Stanford University
Where
Palo Alto and Stanford, United StatesSee the 2 sites
Trial code
Registry title
Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
Status
Recruiting
Phase
Phase 4
People taking part
104 people, planned
Started
13 Jan 2025
Expected to end
15 Dec 2027
Type of study
Interventional, 3 groups
Treatments tested
  • Insulin resistance testing
  • OGTT
  • Fat biopsy
  • DXA scan
  • MRI
  • 1H-MRS
  • Tirzepatide
  • Pioglitazone
Record updated
20 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 30 to 70 with type 2 diabetes and a normal body weight, and for normal-weight adults without diabetes as a comparison group.

Age
30 to 70 years
Sex
All sexes can join.
Disease stage
Type 2 diabetes with HbA1c between 5.7% (39 mmol/mol) and 8% (64 mmol/mol), stable treatment or lifestyle for at least 3 months, and BMI between 19 and 24.9 kg/m². The comparison group has no diabetes (fasting glucose < 100 mg/dL (5.6 mmol/L), A1c < 5.7% (39 mmol/mol)) and the same BMI range.
Earlier treatment
People with diabetes can take any diabetes medicine except insulin and pioglitazone. GLP-1 receptor agonists are allowed if the dose has been stable for 3 months. Nobody who has used pioglitazone before can join.

Main reasons for not taking part

  • Pregnant, planning pregnancy or breastfeeding
  • Body weight changed by more than 2 kg (4 lb) in the last 3 months
  • Significant liver or kidney disease
  • Congestive heart failure or a history of fluid overload
  • Using insulin or weight loss medicines, or past bariatric surgery or liposuction

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Normal-Weight Diabetes (NWD) Group:
  • Age: 30 to 70 years old
  • Diagnosis of Type 2 Diabetes (T2D): Based on a previous diagnosis or confirmed by laboratory testing at screening (A1c > 5.7% or fasting glucose > 100 mg/dL)
  • HbA1c Range: Between 5.7% and 8%, with a stable medication or lifestyle regimen for at least 3 months
  • BMI: Between 19 and 24.9 kg/m²
  • Diabetes Medications: All diabetes medications are allowed, except insulin and pioglitazone. GLP-1 receptor agonists are permitted if the dose has been stable for 3 months
  • Stable Body Weight: Body weight must have been stable (no more than 2 kg change) over the last 3 months; Normal-Weight Control (NWC) Group:
  • Age: 30 to 70 years old
  • No Diagnosis of Diabetes: Fasting plasma glucose < 100 mg/dL and A1c < 5.7%, with no history of glucose-lowering medications
  • BMI: Between 19 and 24.9 kg/m²
  • Stable Body Weight: No more than 2 kg change over the past 3 months. -

Who cannot take part

  • Prior Use of Pioglitazone: Participants who have previously used pioglitazone are excluded to avoid confounding effects of prior drug exposure
  • Use of Weight Loss Medications: Those currently taking weight loss medications are excluded to prevent confounding effects on body weight and metabolic function
  • Bariatric Surgery or Liposuction History: Participants who have had weight-loss surgeries or liposuction are excluded due to alterations in fat tissue and metabolic profiles
  • Unstable Body Weight: Individuals with a body weight change of more than 2 kg in the last 3 months are excluded to ensure stable metabolic conditions
  • Congestive Heart Failure or Fluid Overload History: These conditions are exclusionary due to the risk of fluid retention with pioglitazone
  • Uncontrolled Hypertension: Blood pressure > 160/90 mmHg excludes participants due to increased cardiovascular risk
  • Active Cancer: Individuals with a diagnosis of cancer in the past 3 years (except for skin cancer) are excluded
  • Chronic Inflammatory Diseases: Excluded due to potential effects on metabolic measurements
  • Insulin Use: Participants using insulin are excluded to focus on non-insulin-dependent diabetes
  • Active Psychiatric Disease or Eating Disorders: Individuals with these conditions are excluded due to potential impacts on study compliance and data integrity
  • Substance Abuse: Participants with a history of substance abuse are excluded for similar reasons; -
  • Liver or Kidney Disease: Participants with significant liver disease (ALT > 3x upper limit of normal) or renal disease (creatinine > 1.5 mg/dL) are excluded due to potential safety risks
  • Pregnancy or Lactation: Women who are pregnant, planning to become pregnant, or breastfeeding are excluded due to potential risks to the fetus or infant

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 30 and 70 years old?

Where in United States

  • Stanford UniversityPalo Alto, United StatesContact: Nina Shenoy, BSTaking people
  • Stanford University, Clinical and Translational Research Unit (CTRU)Stanford, United StatesContact: Nina Shenoy, BSNot yet recruiting

About the trial

What the trial wants to find out

This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD), those with overweight type 2 diabetes (OWD), and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.

The 3 groups in the trial

  • Normal weight controlsOther group

    Control

    Treatment: Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, and 1H-MRS

  • Normal weight with diabetes tirzepatide first pioglitazone secondTreatment being tested

    Baseline testing Intervention with tirzepatide for 16 weeks Retesting Washout for 5 weeks Intervention with pioglitazone for 16 weeks Retesting

    Treatment: Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, and Pioglitazone

  • Normal weight with diabetes pioglitazone first, tirzepatide secondTreatment being tested

    Baseline testing Intervention with pioglitazone for 16 weeks Retesting Washout for 5 weeks Intervention with tirzepatide for 16 weeks Retesting

    Treatment: Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, and Pioglitazone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
Plain-language title
Testing pioglitazone or tirzepatide in normal-weight adults with type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06657209, who can take part
Record updated
20 April 2026